Your browser doesn't support javascript.
loading
Sustained inhibition of the NaV1.7 sodium channel by engineered dimers of the domain II binding peptide GpTx-1.
Murray, Justin K; Biswas, Kaustav; Holder, J Ryan; Zou, Anruo; Ligutti, Joseph; Liu, Dong; Poppe, Leszek; Andrews, Kristin L; Lin, Fen-Fen; Meng, Shi-Yuan; Moyer, Bryan D; McDonough, Stefan I; Miranda, Les P.
Affiliation
  • Murray JK; Therapeutic Discovery, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA. Electronic address: jkmurray@amgen.com.
  • Biswas K; Therapeutic Discovery, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA.
  • Holder JR; Therapeutic Discovery, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA.
  • Zou A; Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA.
  • Ligutti J; Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA.
  • Liu D; Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA.
  • Poppe L; Therapeutic Discovery, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA.
  • Andrews KL; Therapeutic Discovery, Amgen Inc., 360 Binney Street, Cambridge, MA 02142, USA.
  • Lin FF; Biologics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA.
  • Meng SY; Biologics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA.
  • Moyer BD; Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA.
  • McDonough SI; Neuroscience, Amgen Inc., 360 Binney Street, Cambridge, MA 02142, USA.
  • Miranda LP; Therapeutic Discovery, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA.
Bioorg Med Chem Lett ; 25(21): 4866-4871, 2015 Nov 01.
Article de En | MEDLINE | ID: mdl-26112439
ABSTRACT
Many efforts are underway to develop selective inhibitors of the voltage-gated sodium channel NaV1.7 as new analgesics. Thus far, however, in vitro selectivity has proved difficult for small molecules, and peptides generally lack appropriate pharmacokinetic properties. We previously identified the NaV1.7 inhibitory peptide GpTx-1 from tarantula venom and optimized its potency and selectivity via structure-guided analoging. To further understand GpTx-1 binding to NaV1.7, we have mapped the binding site to transmembrane segments 1-4 of the second pseudosubunit internal repeat (commonly referred to as Site 4) using NaV1.5/NaV1.7 chimeric protein constructs. We also report that select GpTx-1 amino acid residues apparently not contacting NaV1.7 can be derivatized with a hydrophilic polymer without adversely affecting peptide potency. Homodimerization of GpTx-1 with a bifunctional polyethylene glycol (PEG) linker resulted in a compound with increased potency and a significantly reduced off-rate, demonstrating the ability to modulate the function and properties of GpTx-1 by linking to additional molecules.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Peptides / Ingénierie des protéines / Canal sodique voltage-dépendant NAV1.7 / Bloqueurs de canaux sodiques voltage-dépendants Limites: Humans Langue: En Journal: Bioorg Med Chem Lett Sujet du journal: BIOQUIMICA / QUIMICA Année: 2015 Type de document: Article

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Peptides / Ingénierie des protéines / Canal sodique voltage-dépendant NAV1.7 / Bloqueurs de canaux sodiques voltage-dépendants Limites: Humans Langue: En Journal: Bioorg Med Chem Lett Sujet du journal: BIOQUIMICA / QUIMICA Année: 2015 Type de document: Article
...